Acadia Pharma Stock Drops After Phase 2 Alzheimer's Treatment Misses Primary Endpoint
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Acadia stock tumbled Thursday after the company's experimental Alzheimer's disease psychosis treatment missed the mark in a Phase 2 study.
Despite the setback, Acadia Pharmaceuticals and analysts saw enough encouraging signals to support the continuation of a phase 3 program.
Acadia
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Acadia stock tumbled Thursday after the company's experimental Alzheimer's disease psychosis treatment missed the mark in a Phase 2 study.”
IBD — Bears Chase Down Acadia Pharma After Surprise Alzheimer's Setback“Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a”
fierce biotech — <a href="/biotech/acadia-misses-mark-alzheimers-concludes-phase-3-absolutely-worth-pursuing" hreflang="en">Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing</a>